[go: up one dir, main page]

WO2009005045A1 - 置換ジヒドロイソキノリン誘導体 - Google Patents

置換ジヒドロイソキノリン誘導体 Download PDF

Info

Publication number
WO2009005045A1
WO2009005045A1 PCT/JP2008/061876 JP2008061876W WO2009005045A1 WO 2009005045 A1 WO2009005045 A1 WO 2009005045A1 JP 2008061876 W JP2008061876 W JP 2008061876W WO 2009005045 A1 WO2009005045 A1 WO 2009005045A1
Authority
WO
WIPO (PCT)
Prior art keywords
acceptable salt
pharmacologically acceptable
pharmaceutical agent
intracellular signaling
dihydroisoquinoline derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/061876
Other languages
English (en)
French (fr)
Inventor
Shoichi Saito
Yukari Onishi
Junko Sasaki
Taketoshi Ogawa
Shiho Kozuma
Osamu Ando
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of WO2009005045A1 publication Critical patent/WO2009005045A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

エンドトキシンにより引き起こされる細胞内シグナル伝達あるいは細胞活性化及びそれらに起因する炎症性メディエーターの過剰産生等の細胞応答を抑制する作用を有する置換ジヒドロイソキノリン誘導体、その薬理上許容される塩、それらを有効成分として含有する医薬、それらの製法、及び、エンドトキシンにより引き起こされる細胞内シグナル伝達あるいは細胞活性化およびそれらに起因する細胞応答が関係する敗血症（敗血症性ショック、播種性血管内凝固症候群、多臓器不全など）等の疾患の予防及び／又は治療に優れる、上記置換ジヒドロイソキノリン誘導体を有効成分として含有する医薬を提供する。 　下記一般式（I）：で表される化合物又はその薬理上許容される塩;及び該化合物を有効成分として含有する医薬。
PCT/JP2008/061876 2007-07-04 2008-07-01 置換ジヒドロイソキノリン誘導体 Ceased WO2009005045A1 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007175959 2007-07-04
JP2007-175959 2007-07-04

Publications (1)

Publication Number Publication Date
WO2009005045A1 true WO2009005045A1 (ja) 2009-01-08

Family

ID=40226089

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/061876 Ceased WO2009005045A1 (ja) 2007-07-04 2008-07-01 置換ジヒドロイソキノリン誘導体

Country Status (2)

Country Link
TW (1) TW200914012A (ja)
WO (1) WO2009005045A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012063099A1 (en) 2010-11-08 2012-05-18 Telefonaktiebolaget L M Ericsson (Publ) Method and apparatus for enabling dns redirection in mobile telecommunication systems

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11147876A (ja) * 1997-09-12 1999-06-02 Kanebo Ltd テトラヒドロイソキノリン誘導体およびそれを有効成分とする薬剤
JP2001518090A (ja) * 1997-03-28 2001-10-09 ゼネカ リミテッド 腫瘍壊死因子の阻害に有用な複素環により置換したヒドロキサム酸

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001518090A (ja) * 1997-03-28 2001-10-09 ゼネカ リミテッド 腫瘍壊死因子の阻害に有用な複素環により置換したヒドロキサム酸
JPH11147876A (ja) * 1997-09-12 1999-06-02 Kanebo Ltd テトラヒドロイソキノリン誘導体およびそれを有効成分とする薬剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HARSANYI K. ET AL.: "Isobasic isoquinolines. I. Derivatives of 2- (hydroxyimino)-2-(1-isoquinolinyl)acetic acid and their reduction products", JUSTUS LIEBIGS ANNALEN CHEMIE, vol. 10, 1973, pages 1606 - 1611 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012063099A1 (en) 2010-11-08 2012-05-18 Telefonaktiebolaget L M Ericsson (Publ) Method and apparatus for enabling dns redirection in mobile telecommunication systems

Also Published As

Publication number Publication date
TW200914012A (en) 2009-04-01

Similar Documents

Publication Publication Date Title
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
WO2007135527A3 (en) Benzimidazolyl compounds
EP2178869A4 (en) INDOL COMPOUNDS AS AN INHIBITORS OF CELL NECROSIS
WO2008110314A8 (de) Fluoralkylphenylamidine und deren verwendung als fungizide
TW200728307A (en) Novel spirochromanone derivatives
WO2008005368A3 (en) Piperazines as p2x7 antagonists
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
WO2008022286A3 (en) Small molecule inhibitors of kynurenine-3-monooxygenase
WO2008048867A3 (en) Bicyclic heteroaromatic compounds
ATE433988T1 (de) Phosphoramidatderivate
WO2007131982A3 (de) Substituierte prolinamide, deren herstellung und deren verwendung als arzneimittel
WO2008059370A8 (en) Substituted bicyclocarboxyamide compounds
WO2007126900A3 (en) Antifungal agents
MX2009010302A (es) Derivados de indol que tienen actividad inhibidora de cpla2 y aplicaciones y metodos de produccion.
WO2006113552A8 (en) Cyanoarylamines
MX2013007937A (es) Nuevo derivado de indol o indazol o sal del mismo.
WO2008155666A3 (en) Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases
EP1650194A4 (en) Protein kinase inhibitor
WO2008093838A1 (ja) スルファモイル基を有するピリジルイミダゾリジン誘導体、およびその医薬としての使用
WO2008153129A1 (ja) 尿酸値低下剤
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
WO2007097888A3 (en) Fluoroquinolone carboxylic acid salt compositions
WO2007108011A3 (en) Process for the preparation of highly pure donepezil

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08777727

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08777727

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP